Prescribing information

 

The below content is for healthcare professionals in Great Britain only. If you require information for Northern Ireland please refer to the Northern Ireland prescribing information.

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

SCEMBLIX®▼(asciminib) is the first and only STAMP inhibitor1–3

Learn how the unique MOA of SCEMBLIX enhances its specificity in treating CML.1

SCEMBLIX targets a different site on BCR-ABL1 – the myristoyl pocket1-3

 

In people who do not have CML, the myristoyl pocket is occupied by the N-terminal portion of ABL1, maintaining the protein in an inactive conformation.4,5

In BCR-ABL1, the myristoyl pocket is vacant, activating the kinase.4,5

Image showing the MOA of Scemblix

SCEMBLIX is a first-in-class STAMP inhibitor. Binding specifically to the myristoyl pocket, it potently inactivates BCR-ABL1 via allosteric inhibition.1

With its unique MOA, SCEMBLIX offers a different approach for treating CML.4–6

Learn about the efficacy of SCEMBLIX

EXPLORE THE DATA

ATP, adenosine triphosphate; CML, chronic myeloid leukaemia; MOA, mechanism of action; STAMP, specifically targeting the ABL1 myristoyl pocket; TKI, tyrosine kinase inhibitor.

SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.7

For further information please refer to the Summary of Product Characteristics.

 

References

  1. Réa D, et al. Blood 2021;138(21):2031–2041.
  2. Redaelli S, et al. J Clin Oncol 2009;27(3):469–471.
  3. Schoepfer J, et al. J Med Chem 2018;61(18):8120–8135.
  4. Hughes TP, et al. N Engl J Med 2019;381(24):2315–2326.
  5. Manley PW, et al. Leuk Res 2020;98:106458.
  6. Iacob RE, et al. PLoS One 2011;6(1):e15929.
  7. SCEMBLIX (asciminib) Summary of Product Characteristics.
Rate this content: 
Average: 5 (1 vote)
UK | October 2022 | 212211

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]